WAVEMAN · COMPANY

CAI · Caris Life Sciences, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

CAI

Name: Caris Life Sciences, Inc. (CAI) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Caris Life Sciences, Inc.

HEALTHCARE SERVICES · SERVICES-MEDICAL LABORATORIES · CIK 0002019410

FORM 144 · 5☆ WATCH

INSIDER NET · 180D

-$13.3M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

171

13F, latest reported quarter

REVENUE GROWTH

+97.0%

XBRL, annual

NET MARGIN

-8.4%

CONVERSIONS · 180D

codes C/M, not in net · $3.0M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$13.3M over 180 days

-$14.8M over 90 days

below 78% of Healthcare Services

CONGRESS

no member of Congress has reported trading it

FUNDS

171 funds added or opened last quarter

more than 74% of Healthcare Services

REVENUE

+97.0% year over year

more than 94% of Healthcare Services

MARGIN

-8.4% net margin

below 71% of Healthcare Services

BUYBACKS

$21.4M repurchased, FY to 2026-06-30

below 68% of Healthcare Services

SHORT

5.2% of shares outstanding short · 4.2 days to cover · settled 2026-07-31

more than 74% of Healthcare Services

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

5 insiders have filed intent to sell ($18.4M) and have not sold yet.

171 funds added or opened positions in the latest 13F quarter, of 247 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -31.4%

-31.4%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $13.3M sold by insiders over 180 days, 171 funds added last quarter, $18.4M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

NTRA CSTL PGNY HIMS WGS PRVA TDOC AVAH GH ADUS SERA BDSX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Caris Life Sciences, Inc. insiders sold a net $13.3M of stock across 11 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Spetzler David Baxley

President

SELL

2026-09-04

119,212.0

$3.0M

Spetzler David Baxley

President

SELL

2026-09-03

393,100.0

$9.7M

Spetzler David Baxley

President

SELL

2026-09-03

84,900.0

$2.1M

HALBERT JON

Director

BUY

2026-05-15

68,000.0

$990.1K

Vacirca Jeff L

Director

BUY

2026-05-11

31,050.0

$501.5K

11 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 6 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

FMR LLC

30,923,878.0 sh

$551.1M

J. H. Whitney Equity Partners VI, LLC

11,256,615.0 sh

$200.6M

COATUE MANAGEMENT LLC

9,819,992.0 sh

$175.0M

BRAIDWELL LP

8,256,032.0 sh

$147.1M

Sixth Street Partners Management Company, L.P.

7,369,541.0 sh

$131.3M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

DAVID SPETZLER

FILED 2026-09-04

$3.0M

DAVID SPETZLER

FILED 2026-09-03

$11.9M

GEORGE H POSTE REVOCABLE TRUST

FILED 2026-08-24

$2.6M

GEORGE H POSTE

FILED 2026-08-07

$642.6K

GEORGE H POSTE

FILED 2026-08-03

$325.0K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

iShares Genomics Immunology and Healthcare ETF

$3.9M POSITION · AS OF 2026-04-30

2.4%

Select Medical Technology and Devices Portfolio

$54.4M POSITION · AS OF 2026-02-28

1.5%

Nuveen Quant Mid Cap Growth Fund

$10.0M POSITION · AS OF 2026-04-30

1.5%

Fidelity Disruptive Medicine ETF

$805.6K POSITION · AS OF 2026-02-28

1.3%

Fidelity Advisor Health Care Fund

$34.2M POSITION · AS OF 2026-04-30

1.2%

VIP Health Care Portfolio

$10.5M POSITION · AS OF 2026-03-31

1.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12
REVENUE	$812.0M	$412.3M	$306.1M
OPERATING INCOME	$45.1M	$-257.1M	$-319.6M
NET INCOME	$-68.1M	$-281.9M	$-341.4M
EPS (DILUTED)	-3.22	-10.66	-13.24
OPERATING CASH FLOW	$83.2M	$-245.2M	$-276.1M
CASH	$796.3M	$64.0M	—
LONG-TERM DEBT	$378.8M	$319.4M	—
BUYBACKS	$113.0K	$0	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE